Health-related quality of life (EQ-5D) among type 2 diabetes mellitus patients treated with dapagliflozin over 2 years. - Wikidata - awgldk - TriplyDB

Health-related quality of life (EQ-5D) among type 2 diabetes mellitus patients treated with dapagliflozin over 2 years.

Health-related quality of life (EQ-5D) among type 2 diabetes mellitus patients treated with dapagliflozin over 2 years.

http://www.wikidata.org/entity/Q48086602

about

Sodium-glucose cotransporter-2 inhibitor combination therapy to optimize glycemic control and tolerability in patients with type 2 diabetes: focus on dapagliflozin-metformin Dapagliflozin in patients with type 2 diabetes mellitus.Evaluating the sensitivity of EQ-5D in a sample of patients with type 2 diabetes mellitus in two tertiary health care facilities in Nigeria.Dapagliflozin: a review of its use in patients with type 2 diabetes.Standardizing Clinically Meaningful Outcome Measures Beyond HbA1c for Type 1 Diabetes: A Consensus Report of the American Association of Clinical Endocrinologists, the American Association of Diabetes Educators, the American Diabetes Association, th Patient-reported outcomes among patients with type 2 diabetes mellitus treated with dapagliflozin in a triple-therapy regimen for 52 weeks.Quality-of-life and treatment satisfaction in actual clinical practice of patients with Type 1 diabetes mellitus (T1DM) and hypoglycemia treated with insulin degludec.Dapagliflozin improves treatment satisfaction in overweight patients with type 2 diabetes mellitus: a patient reported outcome study (PRO study).

P2860

Q26752815-CD1CC71F-30AF-4A9A-A4BF-288DC2EC3FDF Q35064363-20D5A9D3-FCFD-4712-A36A-BC538F03B4A4 Q35891995-753117BD-67F1-499F-94FA-50D6AA449E01 Q38267346-EA43CA80-997B-4C76-BC5E-856E566DFBA2 Q47825623-CDEAE088-57ED-4BD4-AA18-2D459E3F4810 Q47920825-122C746C-B6E4-49EB-A2C5-E4923F4984DD Q50195979-56E4A5CC-BC61-471D-AC7D-5BCC183498DE Q51744128-799BCC29-6B57-4242-B79E-1584CCB23E9E

P2860

Health-related quality of life (EQ-5D) among type 2 diabetes mellitus patients treated with dapagliflozin over 2 years.

http://www.wikidata.org/entity/Q48086602

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh-hant

name

Health-related quality of life ...... th dapagliflozin over 2 years.

@en

type

label

Health-related quality of life ...... th dapagliflozin over 2 years.

@en

prefLabel

Health-related quality of life ...... th dapagliflozin over 2 years.

@en

P1433

Q48086602-974C22B7-FA0E-49DF-8512-37AF803956D7

P1476

Q48086602-E17B6816-3BC1-4797-B959-641E30DCFBBF

P2093

Q48086602-03568C05-68AB-4E15-9586-0A45F46451FF

Q48086602-7F6D2666-5769-43C3-9F08-0568C4401685

Q48086602-849B5641-0685-4D13-A7FE-2FB0A81D6BAE

Q48086602-B1E89432-0B94-4D81-ABAF-51FED9378D1C

Q48086602-B8DC4152-65B5-4BF0-A42E-0F30863CC825

P2860

Q48086602-19966FCA-1A4E-4855-BB8A-20FA5F09373B

Q48086602-1A78E58D-E29A-4065-B33D-0DAF34B3B4EC

Q48086602-2590BA49-11BD-4738-9262-90592EAE5ED9

Q48086602-2C84215E-703F-49E2-B20C-718D8EAD4417

Q48086602-33D5A441-E4FA-4B06-B80F-E2E53F85B36D

Q48086602-375841BD-8C01-4FA5-A0A9-17DE9152F577

Q48086602-3C16D3A9-DC1B-4C0E-BDCC-2CD52DEA21F9

Q48086602-52B07F3C-9517-4DA4-BAA3-914BB6E9A98F

Q48086602-5E92C304-72B9-49B9-833F-B17683D25E61

Q48086602-5EA2BB6B-6A61-4137-954A-7259F22DB48D

P304

Q48086602-6D9F80F2-5420-434D-BF70-67C69CCC34B8

P31

Q48086602-93E53BF8-54B2-4FE3-873F-CC8052731275

P356

Q48086602-361C1102-7E5D-41BD-B32F-FCEC244A3ACF

P433

Q48086602-0BE2DD4B-9FE2-47DA-AAD2-529051B0A1B1

P478

Q48086602-CEB186C7-2ADF-433D-A43F-453A030FFA1C

P577

Q48086602-DDFA57DF-8438-4E22-81FC-8AC10E610BB3

P698

Q48086602-09E6F674-9A55-4076-B36D-A94EF754F7FB

P356

P1433

International Journal of Clinical Practice

P1476

Health-related quality of life ...... th dapagliflozin over 2 years.

@en

P2093

A M Langkilde

http://www.w3.org/2001/XMLSchema#string

C D Sjöström

http://www.w3.org/2001/XMLSchema#string

J E Sugg

http://www.w3.org/2001/XMLSchema#string

S Grandy

http://www.w3.org/2001/XMLSchema#string

S Parikh

http://www.w3.org/2001/XMLSchema#string

P2860

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

EuroQol--a new facility for the measurement of health-related quality of life

Prediction of creatinine clearance from serum creatinine

EQ-5D: a measure of health status from the EuroQol Group.

Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment.

Changes in health state utilities with changes in body mass in the Diabetes Prevention Program.

Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes.

Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial.

Measurement of health-related QOL in diabetes mellitus.

P304

486-494

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/IJCP.12341

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

68

http://www.w3.org/2001/XMLSchema#string

P577

2014-02-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24499168

http://www.w3.org/2001/XMLSchema#string